Hengrui's Heng Yi® Approved in China for Dry Eye Disease Treatment

What's Happening? Hengrui Pharma, in collaboration with Novaliq GmbH, has received approval from China's National Medical Products Administration for Heng Yi®, a cyclosporine ophthalmic solution designed to treat dry eye disease (DED). This innovative treatment aims to increase tear secretion and im

Healthy Living

SEE ALL

Trendline

80-Year-Old Linda Kelly Maintains Excellent Fitness with Unique Exercise Routine

Rolling Stone

The Best Infrared Saunas to Relax and Recharge at Home

Trendline

Physical Therapist Advocates for Muscle Building After 70 with Weekly Workouts

What is the story about?

What's Happening?

Hengrui Pharma, in collaboration with Novaliq GmbH, has received approval from China's National Medical Products Administration for Heng Yi®, a cyclosporine ophthalmic solution designed to treat dry eye disease (DED). This innovative treatment aims to increase

tear secretion and improve symptoms associated with DED, a condition affecting a significant portion of the Chinese population. Heng Yi® is notable for being the first water-free cyclosporine solution approved in China, utilizing Novaliq's EyeSol® technology to enhance drug delivery and efficacy.

Why It's Important?

The approval of Heng Yi® addresses a critical unmet need in the management of dry eye disease, offering a new therapeutic option for patients who have limited treatment choices. This development highlights the potential of innovative drug delivery technologies to improve patient outcomes in ophthalmology. The collaboration between Hengrui Pharma and Novaliq also underscores the importance of international partnerships in advancing medical research and expanding access to effective treatments globally.